SLC5A2 and chronic kidney disease: Recently, first-line drug therapy proposed by the Kidney Disease Improving Global Outcomes (KDIGO) 2020 clinical practice guideline for diabetes management in CKD includes RAAS blockade, metformin, SGLT2 inhibitors and statins.40 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) are widely recommended in patients with DKD and albuminuria.